AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 66.6 |
Market Cap | 4.44B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -1.95 |
PE Ratio (ttm) | -41.83 |
Forward PE | n/a |
Analyst | Strong Buy |
Ask | 86.85 |
Volume | 457,981 |
Avg. Volume (20D) | 785,954 |
Open | 84.27 |
Previous Close | 82.91 |
Day's Range | 79.65 - 84.68 |
52-Week Range | 44.02 - 103.81 |
Beta | undefined |
About PRCT
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2...
Analyst Forecast
According to 7 analyst ratings, the average rating for PRCT stock is "Strong Buy." The 12-month stock price forecast is $102, which is an increase of 25.04% from the latest price.
Next Earnings Release
Analysts project revenue of $66.79M, reflecting a 53.25% YoY growth and earnings per share of -0.35, making a -35.19% decrease YoY.
2 months ago · seekingalpha.com
PROCEPT BioRobotics Corporation (PRCT) Q3 2024 Earnings Call TranscriptPROCEPT BioRobotics Corporation (NASDAQ:PRCT ) Q3 2024 Earnings Conference Call October 28, 2024 8:00 AM ET Company Participants Matt Bacso - Vice President, Investor Relations Reza Zadno - Chief Exec...